Physician profile
Timothy A Quinn
NPI 1962453480
$8,639.84
in general payments reported to CMS, 2019-2025
20 companies · $2,505 in 2025
The $2,505 reported for 2025 was more than what 90% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $147 · 2020: $11.16 · 2021: $1,087 · 2022: $1,355 · 2023: $2,106 · 2024: $1,428 · 2025: $2,505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,147 · Travel and Lodging: $892.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,146.62 |
| Travel and Lodging | $891.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,295.48 | 2021-2025 | Clareon, Hydrus Microstent, Rocklatan |
| Sight Sciences, INC. | $1,417.54 | 2021-2025 | Omni Surgical System, Sion Surgical Instrument |
| Abbvie INC. | $1,149.43 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $930.80 | 2022-2025 | Acthar |
| Regeneron Healthcare Solutions, INC. | $561.19 | 2019-2025 | Eylea, Eylea Hd |
| Ocular Therapeutix, INC. | $373.98 | 2020-2025 | Dextenza |
| Bausch & Lomb Americas INC. | $306.23 | 2022-2025 | Infuse, Scoutpro Osmolarity System, Xiidra |
| Biotissue Holdings INC. | $301.36 | 2021-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $274.93 | 2021-2025 | Tecnis Iol |
| Allergan, INC. | $177.81 | 2021-2022 | |
| Alimera Sciences, INC. | $146.20 | 2021 | |
| Boston Scientific Corporation | $145.16 | 2024 | Intracept |
| Astellas Pharma US INC | $135.02 | 2023 | |
| Sun Pharmaceutical Industries INC. | $125.76 | 2021 | |
| Glaukos Corporation | $122.95 | 2019-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rayner Intraocular Lenses Limited | $69.84 | 2022-2025 | Omidria |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $58.18 | 2021 | |
| Oyster Point Pharma, INC. | $20.34 | 2023 | Tyrvaya |
| Genentech USA, INC. | $14.27 | 2022 | |
| Ivantis, INC | $13.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Quinn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.